About | Free Trial

Last Update

2011-05-01T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Anders Heijl?

Dr. Anders Heijl

Chairman of the Department of Ophthalmology

Malmö University Hospital

Malmö University Hospital

Background Information

Employment History

Consultant

Carl Zeiss Meditec AG

Study Director of the Early Manifest Glaucoma Trial, An Inventor

StatPac Inc.

Professor of Ophthalmology, Department of Ophthalmology

Lund University

Education

M.D.

Web References (58 Total References)


These results should be put into ...

georgewalkerbush.org [cached]

These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."

Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said.
Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.


These results should be put into ...

georgewalkerbush.org [cached]

These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."

Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said.
Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.


Glaucoma Treatment

www.tricountyeye.com [cached]

These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."

Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said. Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.


These results should be put into ...

tricountyeye.com [cached]

These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report."Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said."On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."

Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients."This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said.Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced.Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity."The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.


Optometric Management

www.optometricmanagement.com [cached]

Centered around the detection of visual field change, GPA software was developed with Carl Zeiss Meditec by Anders Heijl, M.D., Ph.D., chairman, department of ophthalmology, Malmo University Hospital in Sweden and the principal investigator of the landmark Early Manifest Glaucoma Trial (EMGT).

...
Dr. Heijl and the EMGT study 1 validated the concept that progression is associated with three points changing on three consecutive tests.

Similar Profiles

Other People with this Name

Other people with the name Heijl

Mark Heijl
Johnson Matthey Plc

David Heijl
Esko

Astrid van Heijl
Periscopix Ltd

Birgit Heijl
Dutch Public Prosecution Service

Lars Heijl
Landalatandläkarna, Gothenburg, Sweden

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory